The antitumor effects of interferon-alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line

Journal of Surgical Research

Volumn 116, Issue 1, 2004, Pages 129-136

  Badgwell, Brian ^a   Lesinski, Gregory B ^a   Magro, Cynthia ^a   Abood, Gerard ^a   Skaf, Ayham ^a   Carson III, William ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Interferon alpha; Janus kinase; Malignant melanoma; Murine; Proliferation; Signal transducer and activator of transcription 1 (STAT1)

Indexed keywords

ALPHA INTERFERON; DIMETHYLBENZ[A]ANTHRACENE; STAT1 PROTEIN; TUMOR PROMOTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER SURVIVAL; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; EXPERIMENTAL NEOPLASM; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA B16; MELANOMA CELL; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; WILD TYPE;

EID: 0345829305     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jss.2003.09.005     Document Type: Conference Paper

References (32)

1. Sober A.J. Diagnosis and management of skin cancer. Cancer. 51:1983;2448.
2. Agarwala S.S., Kirkwood J.M. Update on the role of adjuvant interferon for high risk melanoma. Forum (Genova). 10:2000;230.
3. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., Smith T.J., Borden E.C., Blum R.H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma The Eastern Cooperative Oncology Group Trial EST 1684 . J. Clin. Oncol. 14:1996;7.
4. Kirkwood J.M., Ibrahim J.G., Sondak V.K., Richards J., Flaherty L.E., Ernstoff M.S., Smith T.J., Rao U., Steele M., Blum R.H. High- and low-dose interferon alfa-2b in high-risk melanoma First analysis of intergroup trial E1690/S9111/C9190 . J. Clin. Oncol. 18:2000;2444.
5. Kirkwood J.M., Ibrahim J.G., Sosman J.A., Sondak V.K., Agarwala S.S., Ernstoff M.S., Rao U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma Results of intergroup trial E1694/S9512/C509801 . J.Clin. Oncol. 19:2001;2370.
6. Lens M.B., Dawes M. Interferon alfa therapy for malignant melenoma A systematic review of randomized controlled trials . J. Clin. Oncol. 20:2002;1818.
7. Flaherty L.E., Gadgeel S.M. Biochemotherapy of melanoma. Semin. Oncol. 29:2002;446.
8. Bromberg J.F., Horvath C.M., Wen Z., Schreiber R.D., Darnell J.E. Jr. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc. Natl. Acad. Sci. USA. 93:1996;7673.
9. Darnell J.E. Jr, Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 264:1994;1415.
10. Durbin J.E., Hackenmiller R., Simon M.C., Levy D.E. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell. 84:1996;443.
11. Haque S.J., Williams B.R. Signal transduction in the interferon system. Semin. Oncol. 25:1998;14.
12. Leonard W.J., O'Shea J.J. Jaks and STATs Biological implications . Ann. Rev. Immunol. 16:1998;293.
13. Chawla-Sarkar M., Leaman D.W., Jacobs B.S., Tuthill R.J., Chatterjee-Kishore M., Stark G.R., Borden E.C. Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (stat1). J. Interferon Cytokine Res. 22:2002;603.
14. Gallagher C.H., Canfield P.J., Greenoak G.E., Reeve V.E. Characterization and histogenesis of tumors in the hairless mouse produced by low-dosage incremental ultraviolet radiation. J. Invest. Dermatol. 83:1984;169.
15. Berkelhammer J., Oxenhandler R.W., Hook R.R. Jr, Hennessy J.M. Development of a new melanoma model in C57BL/6 mice. Cancer Res. 42:1982;3157.
16. Berkelhammer J., Oxenhandler R.W. Evaluation of premalignant and malignant lesions during the induction of mouse melanomas. Cancer Res. 47:1987;1251.
17. Sadowski H.B., Shuai K., Darnell J.E. Jr, Gilman M.Z. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science. 261:1993;1739.
18. Fleisher T.A., Dorman S.E., Anderson J.A., Vail M., Brown M.R., Holland S.M. Detection of intracellular phosphorylated STAT-1 by flow cytometry. Clin. Immunol. 90:1999;425.
19. Walter M.J., Look D.C., Tidwell R.M., Roswit W.T., Holtzman M.J. Targeted inhibition of interferon-gamma-dependent intercellular adhesion molecule-1 (ICAM-1) expression using dominant-negative Stat1. J. Biol. Chem. 272:1997;28582.
20. Botella-Estrada R., Malet G., Revert F., Dasi F., Crespo A., Sanmartin O., Guillen C., Alino S.F. Antitumor effect of B16 melanoma cells genetically modified with the angiogenesis inhibitor rnasin. Cancer Gene Ther. 8:2001;278.
21. Tessitore A., Pastore L., Rispoli A., Cilenti L., Toniato E., Flati V., Farina A.R., Frati L., Gulino A., Martinotti S. Two gamma-interferon-activation sites (GAS) on the promoter of the human intercellular adhesion molecule (ICAM-1) gene are required for induction of transcription by IFN-gamma. Eur. J. Biochem. 258:1998;968.
22. Wahl W.L., Sussman J.J., Shu S., Chang A.E. Adoptive immunotherapy of murine intracerebral tumors with anti-CD3/interleukin-2-activated tumor-draining lymph node cells. J. Immunother. Emphasis Tumor Immunol. 15:1994;242.
23. Bardeesy N., Wong K.K., DePinho R.A., Chin L. Animal models of melanoma Recent advances and future prospects . Adv.Cancer Res. 79:2000;123.
24. Tietze M.K., Chin L. Murine models of malignant melanoma. Mol. Med. Today. 6:2000;408.
25. Fleischmann C.M., Stanton G.J., Fleischmann W.R. Jr. Enhanced in vivo sensitivity of in vitro interferon-treated B16 melanoma cells to CD8 cells and activated macrophages. J. Interferon Cytokine Res. 16:1996;805.
26. Carson W.E. Interferon-alpha-induced activation of signal transducer and activator of transcription proteins in malignant melanoma. Clin. Cancer Res. 4:1998;2219.
27. Wong L.H., Krauer K.G., Hatzinisiriou I., Estcourt M.J., Hersey P., Tam N.D., Edmondson S., Devenish R.J., Ralph S.J. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J. Biol. Chem. 272:1997;28779.
28. Pansky A., Hildebrand P., Fasler-Kan E., Baselgia L., Ketterer S., Beglinger C., Heim M.H. Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int. J. Cancer. 85:2000;720.
29. Sun W.H., Pabon C., Alsayed Y., Huang P.P., Jandeska S., Uddin S., Platanias L.C., Rosen S.T. Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood. 91:1998;570.
30. Zhou Y., Wang S., Gobl A., Oberg K. Interferon alpha induction of Stat1 and Stat2 and their prognostic significance in carcinoid tumors. Oncology. 60:2001;330.
31. Abril E., Real L.M., Serrano A., Jimenez P., Garcia A., Canton J., Trigo I., Garrido F., Ruiz-Cabello F. Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line. Cancer Immunol.Immunother. 47:1998;113.
32. Ramana C.V., Gil M.P., Schreiber R.D., Stark G.R. Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol. 23:2002;96.